Header

UZH-Logo

Maintenance Infos

Browse by Creators

Navigate back| Up a level
Export as
Number of items: 6.

Gachechiladze, Mariam; Škarda, Josef; Soltermann, Alex; Joerger, Markus (2017). RAD51 as a potential surrogate marker for DNA repair capacity in solid malignancies. International Journal of Cancer, 141(7):1286-1294.

Gachechiladze, Mariam; Škarda, Josef; Kolek, Vítězslav; Grygárková, Ivona; Langová, Kateřina; Bouchal, Jan; Kolář, Zdeněk; Baty, Florent; Stahel, Rolf; Weder, Walter; Soltermann, Alex; Joerger, Markus (2017). Prognostic and predictive value of loss of nuclear RAD51 immunoreactivity in resected non-small cell lung cancer patients. Lung Cancer, 105:31-38.

Driessen, Christoph; Kraus, Marianne; Joerger, Markus; Rosing, Hilde; Bader, Jürgen; Hitz, Felicitas; Berset, Catherine; Xyrafas, Alexandros; Hawle, Hanne; Berthod, Gregoire; Overkleeft, Hermann S; Sessa, Cristiana; Huitema, Alwin; Pabst, Thomas; von Moos, Roger; Hess, Dagmar; Mey, Ulrich J M (2016). Treatment with the HIV protease inhibitor Nelfinavir triggers the unfolded protein response and may overcome proteasome inhibitor resistance of multiple myeloma in combination with bortezomib: a phase I trial (SAKK 65/08). Haematologica, 101(3):346-355.

Joerger, Markus; Thürlimann, Beat; Savidan, Anita; Frick, Harald; Bouchardy, Christine; Konzelmann, Isabelle; Probst-Hensch, Nicole; Ess, Silvia (2012). A population-based study on the implementation of treatment recommendations for chemotherapy in early breast cancer. Clinical Breast Cancer, 12(2):102-109.

Joerger, Markus; Ess, Silvia; Dehler, Silvia; Savidan, Anita; Bouchardy, Christine; Frick, Harald; Konzelmann, Isabelle; Thürlimann, Beat (2012). A population-based study on the patterns of use of different chemotherapy regimens in Swiss patients with early breast cancer. Swiss Medical Weekly, 142:w13571.

Matter-Walstra, Klazien; Joerger, Markus; Kühnel, Ursula; Szucs, Thomas D; Pestalozzi, Bernhard; Schwenkglenks, Matthias (2012). Cost-effectiveness of maintenance pemetrexed in patients with advanced nonsquamous-cell lung cancer from the perspective of the Swiss health care system. Value in Health, 15(1):65-71.

This list was generated on Fri Nov 24 13:07:09 2017 CET.